Journal Club: All Recent News

Head of Biogen's copycat drug unit leaves to join Scangos startup

(Aug 28 2017)

Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects

(Aug 28 2017)

EU regulator clears Samsung Bioepis' Imraldi as biosimilar version of AbbVie's Humira

(Aug 25 2017)

Erelzi (etanercept), by Sandoz, is now available for patients in Canada for the treatment of multiple inflammatory diseases

(Aug 21 2017)

Biocon: Company Statement on status of EMA Dossiers

(Aug 16 2017)

Arkin slams Teva for not foreseeing generics crisis

(Aug 13 2017)

Plans to increase access to cost-effective biosimilar medicines move forward with opening of public consultation – Minister Harris

(Aug 11 2017)

Luye Pharma Boosts Its Product Portfolio in Biomedicine by Acquiring 2 Biological Antibodies

(Aug 10 2017)

Aurobindo Pharma ups the ante in oncology space

(Aug 8 2017)

Physician Views Poll Results – The potential impact of US biosimilar interchangeability in five charts

(Aug 8 2017)

Coherus BioSciences Files Petition for Inter Partes Review of Enbrel Patent 8,163,522

(Aug 7 2017)

Physician Views: Biosimilar interchangeability – will it matter?

(Aug 6 2017)

Spotlight On: Boehringer Ingelheim sets the pace for interchangeable biosimilar status with new study, but implications of this additional regulatory benchmark remain hard to predict

(Aug 2 2017)

Sandoz Erelzi (etanercept) receives positive reimbursement recommendation from Common Drug Review

(Aug 2 2017)

Biosimilar RENFLEXIS (infliximab) available on PBS from 1st August

(Aug 1 2017)

Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration

(Jul 31 2017)

Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin (trastuzumab)

(Jul 31 2017)

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira

(Jul 27 2017)

ViewPoints: Merck & Co. bears its biosimilar teeth with Renflexis, but is greater discounting necessary?

(Jul 25 2017)

Merck & Co., Samsung Bioepis introduce Remicade biosimilar Renflexis in US

(Jul 24 2017)

Pages